Cargando…
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
BACKGROUND: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134372/ https://www.ncbi.nlm.nih.gov/pubmed/36799072 http://dx.doi.org/10.1002/cam4.5628 |
_version_ | 1785031749894406144 |
---|---|
author | Torka, Pallawi Pederson, Levi D. Knopp, Michael V. Poon, David Zhang, Jun Kahl, Brad S. Higley, Howard R. Kelloff, Gary Friedberg, Jonathan W. Schwartz, Lawrence H. Wilson, Wyndham H. Leonard, John P. Bartlett, Nancy L. Schöder, Heiko Ruppert, Amy S. |
author_facet | Torka, Pallawi Pederson, Levi D. Knopp, Michael V. Poon, David Zhang, Jun Kahl, Brad S. Higley, Howard R. Kelloff, Gary Friedberg, Jonathan W. Schwartz, Lawrence H. Wilson, Wyndham H. Leonard, John P. Bartlett, Nancy L. Schöder, Heiko Ruppert, Amy S. |
author_sort | Torka, Pallawi |
collection | PubMed |
description | BACKGROUND: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5‐point scale (5‐PS). METHODS: In CALGB 50303, patients with DLBCL received frontline R‐CHOP or DA‐EPOCH‐R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5‐PS with progression‐free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. In this patient cohort, we retrospectively compared local vs central iPET readings and evaluated associations between local imaging data and survival outcomes. RESULTS: Agreement between local and central review was moderate (kappa = 0.53) for VSS and high (kappa = 0.81) for ∆SUV categories (<66% vs. ≥66%). ∆SUV ≥66% at iPET was significantly associated with PFS (p = 0.03) and OS (p = 0.002), but VSS was not. Associations with PFS/OS when applying local review vs central review were comparable. CONCLUSIONS: These data suggest that local PET interpretation for response determination may be acceptable in clinical trials. Our findings also highlight limitations of VSS and call for incorporation of more objective measures of response assessment in clinical trials. |
format | Online Article Text |
id | pubmed-10134372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101343722023-04-28 Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis Torka, Pallawi Pederson, Levi D. Knopp, Michael V. Poon, David Zhang, Jun Kahl, Brad S. Higley, Howard R. Kelloff, Gary Friedberg, Jonathan W. Schwartz, Lawrence H. Wilson, Wyndham H. Leonard, John P. Bartlett, Nancy L. Schöder, Heiko Ruppert, Amy S. Cancer Med BRIEF COMMUNICATION BACKGROUND: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5‐point scale (5‐PS). METHODS: In CALGB 50303, patients with DLBCL received frontline R‐CHOP or DA‐EPOCH‐R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5‐PS with progression‐free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. In this patient cohort, we retrospectively compared local vs central iPET readings and evaluated associations between local imaging data and survival outcomes. RESULTS: Agreement between local and central review was moderate (kappa = 0.53) for VSS and high (kappa = 0.81) for ∆SUV categories (<66% vs. ≥66%). ∆SUV ≥66% at iPET was significantly associated with PFS (p = 0.03) and OS (p = 0.002), but VSS was not. Associations with PFS/OS when applying local review vs central review were comparable. CONCLUSIONS: These data suggest that local PET interpretation for response determination may be acceptable in clinical trials. Our findings also highlight limitations of VSS and call for incorporation of more objective measures of response assessment in clinical trials. John Wiley and Sons Inc. 2023-02-17 /pmc/articles/PMC10134372/ /pubmed/36799072 http://dx.doi.org/10.1002/cam4.5628 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | BRIEF COMMUNICATION Torka, Pallawi Pederson, Levi D. Knopp, Michael V. Poon, David Zhang, Jun Kahl, Brad S. Higley, Howard R. Kelloff, Gary Friedberg, Jonathan W. Schwartz, Lawrence H. Wilson, Wyndham H. Leonard, John P. Bartlett, Nancy L. Schöder, Heiko Ruppert, Amy S. Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis |
title | Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis |
title_full | Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis |
title_fullStr | Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis |
title_full_unstemmed | Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis |
title_short | Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis |
title_sort | is local review of positron emission tomography scans sufficient in diffuse large b‐cell lymphoma clinical trials? a calgb 50303 analysis |
topic | BRIEF COMMUNICATION |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134372/ https://www.ncbi.nlm.nih.gov/pubmed/36799072 http://dx.doi.org/10.1002/cam4.5628 |
work_keys_str_mv | AT torkapallawi islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT pedersonlevid islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT knoppmichaelv islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT poondavid islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT zhangjun islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT kahlbrads islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT higleyhowardr islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT kelloffgary islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT friedbergjonathanw islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT schwartzlawrenceh islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT wilsonwyndhamh islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT leonardjohnp islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT bartlettnancyl islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT schoderheiko islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis AT ruppertamys islocalreviewofpositronemissiontomographyscanssufficientindiffuselargebcelllymphomaclinicaltrialsacalgb50303analysis |